Page last updated: 2024-08-21

quinazolines and hki 272

quinazolines has been researched along with hki 272 in 57 studies

Research

Studies (57)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	11 (19.30)	29.6817
2010's	40 (70.18)	24.3611
2020's	6 (10.53)	2.80

Authors

Authors	Studies
Bell, DW; Brannigan, BW; Driscoll, DR; Fidias, P; Godin-Heymann, N; Haber, DA; Harris, PL; Isselbacher, KJ; Kwak, EL; Lynch, TJ; McGinnis, JP; Okimoto, RA; Rabindran, SK; Settleman, J; Sharma, SV; Sordella, R; Wissner, A	1
Al-Hashem, R; Bronson, RT; Discafani, CM; Eck, M; Glatt, KA; Horner, JW; Ji, H; Jung, BL; Li, D; Maher, E; McNamara, K; Meyerson, M; Mitchell, A; Protopopov, A; Rabindran, SK; Sasaki, H; Shapiro, GI; Shimamura, T; Sun, Y; Thomas, RK; Wong, KK; Xia, H; Yuza, Y; Zhao, X	1
Al-Hashem, R; Bronson, RT; Chen, L; Chirieac, LR; Jänne, PA; Ji, H; Johnson, BE; Kim, W; Kobayashi, S; Li, D; Mahmood, U; McNamara, K; Mitchell, A; Padera, R; Shapiro, GI; Sharpless, NE; Shimamura, T; Sun, Y; Tenen, D; Weissleder, R; Wong, KK	1
Arteaga, CL	1
Glatt, KA; Greulich, H; Ji, H; Lowell, AM; Meyerson, M; Minami, Y; Shah, K; Shapiro, GI; Shimamura, T; Thomas, RK; Wong, KK	1
Sequist, LV	1
Chen, TH; Feng, W; Glatt, KA; Greulich, H; Ji, H; Jiang, J; Lee, JC; Meyerson, M; Minami, Y; Shapiro, G; Shimamura, T; Wong, KK; Woo, MS; Yanagisawa, H; Yuza, Y	1
Brannigan, BW; Godin-Heymann, N; Haber, DA; Lamb, J; Maheswaran, S; McDermott, U; Settleman, J; Ulkus, L	1
Riely, GJ	1
Amir, E; Ocaña, A	1
Iwata, K; Yamashita, T	1
Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Guiu, S	1
Belani, CP	1
Früh, M	1
Pandiella, A; Sánchez-Martín, M	1
Gong, Y; Pao, W	1
Azim, HA; de Azambuja, E; Loi, S; Metzger-Filho, O; Piccart, M; Saini, KS; Sotiriou, C	1
Chudenko, VA; Dashian, GA; Filatova, LV; Gershanovich, ML; Latipova, DKh; Luk'ianchikova, VS; Paltuev, RM; Semiglazov, VV; Semiglazova, TIu	1
Awada, A; Bozovic-Spasojevic, I; Chow, L	1
Chen, L; Guan, X; Li, D; Nie, W; Shao, J; Tang, L; Wang, Y; Zhang, H	1
Antalffy, G; Hegedüs, C; Kéri, G; Német, K; Orfi, L; Ozvegy-Laczka, C; Sarkadi, B; Settleman, J; Szakács, G; Truta-Feles, K; Váradi, A; Várady, G	1
Amir, E; Bouganim, N; Clemons, M; Fralick, M; Hilton, JF	1
Dziadziuszko, R; Jassem, J	1
Bozovic-Spasojevic, I; de Azambuja, E; Zardavas, D	1
Aronson, AB; Bose, R; Ding, L; Ellis, MJ; Goel, N; Kavuri, SM; Koboldt, DC; Li, S; Ma, CX; Mardis, ER; Monsey, J; Searleman, AC; Shen, D; Shen, W	1
Majem, M; Pallarès, C	1
Aherne, ST; Clynes, M; Crown, J; Doolan, P; Madden, SF; O'Connor, R; O'Neill, F	1
Awada, A; Bonneterre, J; Germa, C; Geyer, CE; Ito, Y; Kim, SB; Lang, I; Martin, M; Ro, J; Vermette, J; Wang, K	1
Kümler, I; Nielsen, DL; Tuxen, MK	1
Gyõrffy, B; Mihály, Z	1
Beyer, WF; Gooden, D; Liu, L; Soderblom, EJ; Spector, NL; Toone, EJ; Walder, H; Xia, W; Zhao, S	1
Breslin, S; Corcoran, C; Crown, J; Ghobrial, IM; Gogarty, M; O'Driscoll, L; Rani, S	1
Munster, PN; Zhang, X	1
Eisenstein, M	1
Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B	1
Chiba, M; Shibata, Y	1
Kim, S; Lee, J; Lee, JE; Nam, SJ; Oh, SJ	1
Hida, T; Jangchul, P; Kobayashi, Y; Kondo, C; Mitsudomi, T; Mizuuchi, H; Nishio, K; Sato, K; Shimoji, M; Suda, K; Takemoto, T; Togashi, Y; Tomizawa, K; Yatabe, Y	1
Di Luca, A; Henry, M; Meleady, P; O'Connor, R	1
Bertotti, A; Bose, R; Cottino, F; Galimi, F; Jacobs, SA; Jain, N; Kavuri, SM; Leto, SM; Migliardi, G; Monsey, J; Searleman, AC; Shen, W; Trusolino, L	1
Arteaga, CL; Bose, R; Button, B; Chu, D; Cidado, J; Cimino-Mathews, A; Cochran, RL; Cravero, K; Croessmann, S; Dalton, WB; Erlanger, B; Kavuri, SM; Konstantopoulos, K; Kyker-Snowman, K; Lauring, J; Manto, KM; Park, BH; Parsons, HA; Red Brewer, M; Rosen, DM; Wong, HY; Yankaskas, CL; Zabransky, DJ	1
Barlesi, F; Beau-Faller, M; Besse, B; Cappuzzo, F; Cortot, A; Dansin, E; Filleron, T; Fournel, P; Früh, M; Gautschi, O; Mazières, J; Milia, J; Monnet, I; Moro-Sibilot, D; Peters, S; Pless, M; Rosell, R; Westeel, V; Wislez, M	1
Chen, T; Gao, N; Hu, Y; Huang, X; Jia, T; Jin, G; Jin, Z; Liu, B; Peng, B; Wang, Z; Zhang, N	1
Breslin, S; Lowry, MC; O'Driscoll, L	1
Arteaga, CL; Berger, MF; Brewer, MR; Cross, D; Cutler, RE; Hanker, AB; He, J; Hyman, DM; Koch, JP; Lalani, AS; Lanman, R; Lovly, CM; Meiler, J; Miller, V; Nagy, R; Sheehan, JH; Sliwoski, GR; Solit, DB	1
Collins, DM; Crown, J; Davies, A; Edwards, C; Gately, K; Hughes, C; Madden, SF; O'Byrne, KJ; O'Donovan, N	1
Ahn, HJ; Bhatt, L; Kim, YH; Lee, WK; Nam, HW; Yang, Z	1
Bucher, E; Chin, K; Dane, M; Gray, JW; Heiser, LM; Jonas, O; Kilburn, D; Korkola, JE; Liby, T; Liu, M; Mills, GB; Nederlof, M; Smith, R; Sudar, D; Tatarova, Z; Thompson, W; Watson, SS; Whitman, M	1
Duchnowska, R; Jassem, J; Loibl, S	1
Aisner, J; Burley, SK; Castellano, GM; Ganesan, S; Pine, SR; Vallat, B; Yu, HA	1
Hata, AN; Klempner, SJ	1
Booth, L; Dent, P; Hancock, JF; Hoff, DV; Poklepovic, A	1
Gelmon, KA; Tesch, ME	1
Boikos, SA; Dozmorov, MG; E Koblinski, J; Faber, AC; Fairchild, CK; Floros, KV; Hu, B; Jacob, S; Kurupi, R; Puchalapalli, M; Scaltriti, M	1
Isaacs, C; O'Regan, R; O'Shaughnessy, JA	1
Arribas, J; Chandarlapaty, S; de Stanchina, E; Ferraro, E; Kulick, A; Lahuerta, EJA; Li, Q; Morales, CB; Razavi, P; Reis-Filho, J; Rosen, N; Ross, D; Safonov, A; Smith, AE; Solit, DB	1
Bachelot, T; Bailleux, C; Darlix, A; Jacot, W	1

Reviews

18 review(s) available for quinazolines and hki 272

Article	Year
EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. Cancer cell, 2006, Volume: 9, Issue:6 Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinolines; Signal Transduction	2006
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. The oncologist, 2007, Volume: 12, Issue:3 Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Morpholines; Organic Chemicals; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines	2007
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:6 Suppl 2 Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prognosis; Quinazolines; Quinolines; Risk Assessment; Survival Analysis; Treatment Outcome	2008
Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions. Cancer treatment reviews, 2009, Volume: 35, Issue:8 Topics: Afatinib; Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Forecasting; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Morpholines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Trastuzumab; Up-Regulation	2009
[Management of metastatic HER2-positive breast cancer: present and future]. Bulletin du cancer, 2010, Volume: 97, Issue:3 Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Disease Progression; Female; Heart; Humans; Lactams, Macrocyclic; Lapatinib; Letrozole; Neoplasm Proteins; Nitriles; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab; Triazoles	2010
The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors. Cancer investigation, 2010, Volume: 28, Issue:4 Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Morpholines; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Quinolines	2010
The search for improved systemic therapy of non-small cell lung cancer--what are today's options? Lung cancer (Amsterdam, Netherlands), 2011, Volume: 72, Issue:3 Topics: Afatinib; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Precision Medicine; Protein-Tyrosine Kinases; Quinazolines; Quinolines	2011
Beyond trastuzumab: new treatment options for HER2-positive breast cancer. Breast (Edinburgh, Scotland), 2011, Volume: 20 Suppl 3 Topics: Adult; Antibodies, Monoclonal, Humanized; Belgium; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Prognosis; Protein Kinase Inhibitors; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Risk Assessment; Survival Analysis; Trastuzumab	2011
[Novel target therapies used in breast cancer management]. Voprosy onkologii, 2011, Volume: 57, Issue:5 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Humans; Lapatinib; Molecular Targeted Therapy; Mutation; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; RANK Ligand; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab	2011
New therapies in HER2-positive breast cancer: a major step towards a cure of the disease? Cancer treatment reviews, 2012, Volume: 38, Issue:5 Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab	2012
Dual blockade of HER2 - twice as good or twice as toxic? Clinical oncology (Royal College of Radiologists (Great Britain)), 2012, Volume: 24, Issue:9 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab	2012
Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer. Current opinion in oncology, 2012, Volume: 24, Issue:6 Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms, Hormone-Dependent; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab	2012
An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013, Volume: 15, Issue:5 Topics: Afatinib; Aminoquinolines; Angiogenesis Inhibitors; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lapatinib; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Quinolines	2013
A systematic review of dual targeting in HER2-positive breast cancer. Cancer treatment reviews, 2014, Volume: 40, Issue:2 Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Neoadjuvant Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Up-Regulation	2014
[HER2-positive breast cancer: available targeted agents and biomarkers for therapy response]. Magyar onkologia, 2013, Volume: 57, Issue:3 Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Everolimus; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Quinolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab	2013
Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. Cancer treatment reviews, 2018, Volume: 67 Topics: Afatinib; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Receptor, ErbB-2	2018
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars. Drugs, 2020, Volume: 80, Issue:17 Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast; Breast Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Immunoconjugates; Lapatinib; Mastectomy; Maytansine; Medical Oncology; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxazoles; Practice Guidelines as Topic; Pyridines; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab	2020
Bulletin du cancer, 2021, Volume: 108, Issue:11S Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cranial Irradiation; Disease Progression; Female; Humans; Lapatinib; Life Expectancy; Magnetic Resonance Imaging; Metastasectomy; Middle Aged; Oxazoles; Pyridines; Quinazolines; Quinolines; Radiosurgery; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab	2021

Trials

2 trial(s) available for quinazolines and hki 272

Article	Year
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Nausea; Quinazolines; Quinolines; Receptor, ErbB-2; Treatment Outcome; Vomiting	2013
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Nov-10, Volume: 32, Issue:32 Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Paresthesia; Quinazolines; Quinolines; Receptor, ErbB-2; Syndrome; Trastuzumab; Treatment Outcome	2014

Article

Year

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.

European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:18

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Nausea; Quinazolines; Quinolines; Receptor, ErbB-2; Treatment Outcome; Vomiting

2013

Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Nov-10, Volume: 32, Issue:32

Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Paresthesia; Quinazolines; Quinolines; Receptor, ErbB-2; Syndrome; Trastuzumab; Treatment Outcome

2014

Other Studies

37 other study(ies) available for quinazolines and hki 272

Article	Year
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proceedings of the National Academy of Sciences of the United States of America, 2005, May-24, Volume: 102, Issue:21 Topics: Aminoquinolines; Aniline Compounds; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplasm Recurrence, Local; Organic Chemicals; Phosphorylation; Quinazolines; Quinolines; Receptor, ErbB-2; Sequence Analysis, DNA; Signal Transduction; Tumor Cells, Cultured	2005
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2006, May-16, Volume: 103, Issue:20 Topics: Animals; Antineoplastic Agents; Cell Line; Cyclin-Dependent Kinase Inhibitor p16; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Knockout; Mutation; Protein Isoforms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Tumor Suppressor Protein p14ARF	2006
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer cell, 2006, Volume: 9, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Protein Structure, Tertiary; Quinazolines; Quinolines	2006
Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer research, 2006, Jul-01, Volume: 66, Issue:13 Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Transformed; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Interleukin-3; Lung Neoplasms; Quinazolines; Quinolines; Receptor, ErbB-2	2006
Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer biology & therapy, 2007, Volume: 6, Issue:5 Topics: Alleles; Amino Acid Substitution; Animals; Cell Survival; Cells, Cultured; DNA Primers; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Peptide Fragments; Phosphorylation; Point Mutation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Quinazolines; Quinolines; Retroviridae; Sequence Deletion	2007
The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Molecular cancer therapeutics, 2008, Volume: 7, Issue:4 Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cells, Cultured; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Mice; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Quinolines	2008
[New development in the treatment of breast cancer. II. Future anti-HER2 therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:13 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab	2009
Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications. International journal of cancer, 2012, Jul-01, Volume: 131, Issue:1 Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Morpholines; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab	2012
EGFR mutant lung cancer. Current topics in microbiology and immunology, 2012, Volume: 355 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Quinolines	2012
Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy. International journal of oncology, 2012, Volume: 40, Issue:6 Topics: Afatinib; Antineoplastic Agents; Catalytic Domain; Crystallography, X-Ray; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Models, Molecular; Molecular Targeted Therapy; Mutation, Missense; Neoplasms; Protein Binding; Protein Structure, Secondary; Quinazolines; Quinolines	2012
Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. Biochemical pharmacology, 2012, Aug-01, Volume: 84, Issue:3 Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Neoplasm Proteins; Piperidines; Protein Binding; Quinazolines; Quinolines	2012
Epidermal growth factor receptor (EGFR) inhibitors and derived treatments. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 10 Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Quinazolines; Quinolines; Translational Research, Biomedical; Treatment Outcome	2012
Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer discovery, 2013, Volume: 3, Issue:2 Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Drug Resistance, Neoplasm; Female; Gene Amplification; Gene Expression; Humans; Lapatinib; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Nude; Models, Molecular; Molecular Sequence Data; Mutation; NIH 3T3 Cells; Protein Structure, Tertiary; Quinazolines; Quinolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Sequence Homology, Amino Acid; Transplantation, Heterologous	2013
A gene expression profile indicative of early stage HER2 targeted therapy response. Molecular cancer, 2013, Jul-01, Volume: 12 Topics: Afatinib; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2; Time Factors	2013
Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosis. PloS one, 2014, Volume: 9, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Catalytic Domain; Cell Line, Tumor; Cell Nucleus; Cross-Linking Reagents; Drug Resistance, Neoplasm; Female; Ficusin; Humans; Lapatinib; Molecular Targeted Therapy; Protein Kinase Inhibitors; PUVA Therapy; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Ultraviolet Rays	2014
miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Molecular cancer, 2014, Mar-24, Volume: 13 Topics: Anoikis; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MicroRNAs; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, IGF Type 1	2014
New protein kinase inhibitors in breast cancer: afatinib and neratinib. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:9 Topics: Afatinib; Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2	2014
Clinical trials: More trials, fewer tribulations. Nature, 2014, May-29, Volume: 509, Issue:7502 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Crizotinib; DNA Mutational Analysis; Drug Approval; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Patient Selection; Proto-Oncogene Proteins B-raf; Pyrazoles; Pyridines; Quinazolines; Quinolines; Sample Size	2014
The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib. Drug metabolism and disposition: the biological fate of chemicals, 2015, Volume: 43, Issue:3 Topics: Adenine; Afatinib; Animals; Area Under Curve; Cytosol; Dogs; Glutathione; Hepatocytes; Humans; Kidney; Liver; Macaca fascicularis; Male; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Quinolines; Rats	2015
Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells. Oncology reports, 2015, Volume: 34, Issue:3 Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Estrogen Receptor alpha; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Quinazolines; Quinolines; Receptor, ErbB-2; Tamoxifen	2015
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Dec-01, Volume: 21, Issue:23 Topics: Afatinib; Animals; Cell Line, Tumor; Databases, Genetic; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gene Expression; Gene Frequency; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Models, Molecular; Molecular Conformation; Mutation; Mutation Rate; Protein Kinase Inhibitors; Quinazolines; Quinolines; Structure-Activity Relationship; Transfection; Treatment Outcome	2015
Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2015, Aug-04, Volume: 23 Topics: Afatinib; Breast Neoplasms; Cell Line, Tumor; Chromatography, Liquid; Female; Humans; Lapatinib; Mass Spectrometry; Protein Kinase Inhibitors; Proteomics; Quinazolines; Quinolines; Receptor, ErbB-2	2015
HER2 activating mutations are targets for colorectal cancer treatment. Cancer discovery, 2015, Volume: 5, Issue:8 Topics: Afatinib; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cell Transformation, Neoplastic; Colorectal Neoplasms; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Humans; Molecular Targeted Therapy; Mucous Membrane; Mutation; Quinazolines; Quinolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays	2015
HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proceedings of the National Academy of Sciences of the United States of America, 2015, Nov-10, Volume: 112, Issue:45 Topics: Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Flow Cytometry; Gene Targeting; HEK293 Cells; Humans; Immunoblotting; Lapatinib; Mutation, Missense; Neoplasms; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Thiazoles	2015
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; ErbB Receptors; Europe; Female; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome	2016
Ethacrynic acid improves the antitumor effects of irreversible epidermal growth factor receptor tyrosine kinase inhibitors in breast cancer. Oncotarget, 2016, Sep-06, Volume: 7, Issue:36 Topics: Afatinib; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Ethacrynic Acid; Female; Humans; MAP Kinase Signaling System; MCF-7 Cells; Mice, Inbred BALB C; Protein Kinase Inhibitors; Quinazolines; Quinolines; Wnt Signaling Pathway; Xenograft Model Antitumor Assays	2016
Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4. British journal of cancer, 2017, Feb-28, Volume: 116, Issue:5 Topics: Afatinib; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cytochrome P-450 CYP3A; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab; Up-Regulation	2017
An Acquired Cancer discovery, 2017, Volume: 7, Issue:6 Topics: Afatinib; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2	2017
Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines. Cellular immunology, 2017, Volume: 319 Topics: Afatinib; Antineoplastic Agents; Cell Line, Tumor; Cytotoxicity, Immunologic; Drug Interactions; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; L-Lactate Dehydrogenase; Lapatinib; MCF-7 Cells; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab	2017
Suppressors for Human Epidermal Growth Factor Receptor 2/4 (HER2/4): A New Family of Anti-Toxoplasmic Agents in ARPE-19 Cells. The Korean journal of parasitology, 2017, Volume: 55, Issue:5 Topics: Afatinib; Aminoquinolines; Aniline Compounds; Animals; Cell Line; Gefitinib; Humans; Mice, Inbred BALB C; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Quinolines; Receptor, ErbB-2; Toxoplasma; Tyrphostins	2017
Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell systems, 2018, Mar-28, Volume: 6, Issue:3 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Databases, Genetic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; High-Throughput Screening Assays; Humans; Lapatinib; MCF-7 Cells; Mice; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Tumor Microenvironment; Xenograft Model Antitumor Assays	2018
A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019, Volume: 14, Issue:11 Topics: Acrylamides; Adenocarcinoma of Lung; Aged; Aniline Compounds; Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines; Quinolines; Tumor Stem Cell Assay	2019
Sequence, Treat, Repeat: Addressing Resistance in EGFR-Mutant NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019, Volume: 14, Issue:11 Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mutation; Quinazolines; Quinolines	2019
Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate]. Cellular signalling, 2020, Volume: 68 Topics: Cell Line, Tumor; Cell Survival; Humans; MAP Kinase Signaling System; Models, Biological; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Quinolines; Receptor, ErbB-3; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases; Valproic Acid	2020
Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors. Cell death & disease, 2021, 02-15, Volume: 12, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cyclic N-Oxides; Drug Synergism; Female; Gene Amplification; Humans; Indoles; Indolizines; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Oxazoles; Protein Kinase Inhibitors; Pyridines; Pyridinium Compounds; Quinazolines; Quinolines; Random Allocation; Receptor, ErbB-2; Sulfonamides; Xenograft Model Antitumor Assays	2021
Neratinib: an option for HER2-positive metastatic breast cancer. Clinical advances in hematology & oncology : H&O, 2020, Volume: 18 Suppl 15, Issue:9 Topics: Ado-Trastuzumab Emtansine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Disease Management; Female; Fulvestrant; Humans; Neoplasm Metastasis; Oxazoles; Pyridines; Quality of Life; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab	2020
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nature communications, 2021, 11-18, Volume: 12, Issue:1 Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; MAP Kinase Signaling System; Mutation; Oxazoles; Protein Kinase Inhibitors; Pyridines; Quinazolines; Quinolines; Receptor, ErbB-2; Tumor Escape	2021